background: interferon-free treatments for hepatitis c have been recently available. they can cure over 95% of patients within 12 weeks without significant side effects. a combination of daclatasvir and sofosbuvir has been particularly useful as it is effective against all genotypes of hepatitis c virus (hcv). the combination of sofosbuvir and daclatasvir in a single pill has been recently manu...

Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and treatment are significant health organizations’ concerns worldwide. Although there is no proven drug license against the virus, a variety of components have under investigation. Objectives: In this regard, present study was intended to evaluate consequences Sovodak (sofosbuvir/ daclatasvir) in COVID-19 patie...

BACKGROUND The combination of sofosbuvir and daclatasvir is a potent, pangenotypic regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited countries where newer, expensive combinations are not available. This has been widely tested on genotype 4. However, Phase III trials this other genotypes have cost prohibitive. With the introduction generic, low-cost daclatasvi...